A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Phase 3
4,200
about 3.8 years
18+
107 sites in AL, CA, CT +23
About this study
This trial is testing whether vicadrostat, combined with empagliflozin, helps people with heart failure who have a weak left side of their heart. Participants will take either vicadrostat/empagliflozin or placebo/empagliflozin tablets daily for up to 3.5 years while continuing their regular heart failure treatment. It team will monitor participants' health and symptoms, comparing outcomes between the two groups.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take empagliflozin
- 3.Take vicadrostat
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
oral (Oral Tablet)
Secondary: Absolute change from baseline in KCCQ-OSS at Week 52, Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire- Clinical Summary Score (KCCQ-CSS) at Week 32, Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire- Overall Summary Score (KCCQ-OSS) at Week 32, Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 52, Absolute change from baseline in diastolic blood pressure (DBP) [mmHg] at Week 32 in participants with baseline DBP ≥ 80 mmHg, Absolute change from baseline in systolic blood pressure (SBP) [mmHg] at Week 32 in participants with baseline SBP ≥ 130 mmHg, Key secondary endpoint: Absolute change from baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 32, Time to first occurrence of death from kidney failure, chronic dialysis* or renal transplant or onset of sustained reduction of ≥ 50% estimated glomerular filtration rate (eGFR) or onset of sustained eGFR (CKD-EPI)cr < 10 mL/min/1.73 m²
Cardiology / Heart